This company has been marked as potentially delisted and may not be actively trading. Nuwellis (CHFS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CHFS vs. NRXS, QTI, VRAYQ, VIVE, ELMD, TARA, AVTX, ANIK, OKYO, and AGENShould you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include NeurAxis (NRXS), QT Imaging (QTI), ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), Protara Therapeutics (TARA), Avalo Therapeutics (AVTX), Anika Therapeutics (ANIK), OKYO Pharma (OKYO), and Agenus (AGEN). These companies are all part of the "medical" sector. Nuwellis vs. Its Competitors NeurAxis QT Imaging ViewRay Viveve Medical Electromed Protara Therapeutics Avalo Therapeutics Anika Therapeutics OKYO Pharma Agenus NeurAxis (NASDAQ:NRXS) and Nuwellis (NASDAQ:CHFS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Does the media prefer NRXS or CHFS? In the previous week, NeurAxis had 5 more articles in the media than Nuwellis. MarketBeat recorded 5 mentions for NeurAxis and 0 mentions for Nuwellis. NeurAxis' average media sentiment score of 0.26 beat Nuwellis' score of 0.00 indicating that NeurAxis is being referred to more favorably in the media. Company Overall Sentiment NeurAxis Neutral Nuwellis Neutral Which has more risk & volatility, NRXS or CHFS? NeurAxis has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Do analysts rate NRXS or CHFS? NeurAxis presently has a consensus target price of $7.00, suggesting a potential upside of 190.46%. Given NeurAxis' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeurAxis is more favorable than Nuwellis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuwellis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, NRXS or CHFS? NeurAxis has higher earnings, but lower revenue than Nuwellis. NeurAxis is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurAxis$2.93M5.93-$14.63M-$0.99-2.43Nuwellis$5.51M6.07-$18.11M-$279.28-0.02 Do insiders and institutionals hold more shares of NRXS or CHFS? 11.8% of NeurAxis shares are held by institutional investors. Comparatively, 65.1% of Nuwellis shares are held by institutional investors. 26.4% of NeurAxis shares are held by company insiders. Comparatively, 0.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is NRXS or CHFS more profitable? Nuwellis has a net margin of -254.26% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Nuwellis' return on equity.Company Net Margins Return on Equity Return on Assets NeurAxis-492.76% N/A -641.25% Nuwellis -254.26%-173.61%-131.01% SummaryNeurAxis beats Nuwellis on 10 of the 16 factors compared between the two stocks. Get Nuwellis News Delivered to You Automatically Sign up to receive the latest news and ratings for CHFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHFS vs. The Competition Export to ExcelMetricNuwellisElectromedical Equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.45M$28.58M$5.67B$9.82BDividend YieldN/AN/A3.79%4.07%P/E Ratio-0.112.8230.5825.12Price / Sales6.07208.67460.38114.01Price / CashN/A41.3637.4059.05Price / Book0.432.129.096.18Net Income-$18.11M-$2.66M$3.25B$264.89M Nuwellis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHFSNuwellisN/A$5.54-1.8%N/A+148.5%$33.45M$5.51M-0.1166Gap DownNRXSNeurAxis2.8374 of 5 stars$2.49+2.5%$7.00+181.1%-23.1%$17.97M$2.93M-1.3519Short Interest ↑QTIQT ImagingN/A$1.90+2.7%N/A+321.9%$10.72M$4.00M0.00N/AGap DownVRAYQViewRayN/AN/AN/AN/A$18K$102.21M0.00300High Trading VolumeVIVEViveve MedicalN/A$0.00flatN/A-66.7%$1K$6.83M0.0070ELMDElectromed1.3271 of 5 stars$19.34+1.0%$33.50+73.2%+31.3%$162.19M$61.44M25.79160TARAProtara Therapeutics2.1618 of 5 stars$3.07-1.0%$19.60+538.4%+47.8%$119.60MN/A-1.9030News CoverageEarnings ReportAnalyst RevisionAVTXAvalo Therapeutics3.4979 of 5 stars$9.36+3.9%$30.00+220.5%-2.6%$118.44M$440K0.0040News CoverageAnalyst ForecastShort Interest ↓Gap UpANIKAnika Therapeutics4.3692 of 5 stars$8.72+6.2%$18.00+106.4%-65.4%$118.37M$119.91M-2.10300OKYOOKYO Pharma3.1509 of 5 stars$2.96-5.1%$7.00+136.5%+170.4%$117.35MN/A0.007Gap UpAGENAgenus4.0066 of 5 stars$4.81+12.6%$16.33+239.6%-10.4%$117.07M$103.46M-0.67440News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionGap Up Related Companies and Tools Related Companies NRXS Alternatives QTI Alternatives VRAYQ Alternatives VIVE Alternatives ELMD Alternatives TARA Alternatives AVTX Alternatives ANIK Alternatives OKYO Alternatives AGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHFS) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuwellis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.